Last reviewed · How we verify
NPC-16 Continuous Dosing Regimen Group
NPC-16 is a small molecule that targets the sphingosine-1-phosphate receptor 1 (S1PR1) to modulate immune cell trafficking.
NPC-16 is a small molecule that targets the sphingosine-1-phosphate receptor 1 (S1PR1) to modulate immune cell trafficking. Used for Relapsing forms of multiple sclerosis.
At a glance
| Generic name | NPC-16 Continuous Dosing Regimen Group |
|---|---|
| Also known as | Levonorgestrel 0.09mg, Ethinylestradiol 0.02mg |
| Sponsor | Nobelpharma |
| Drug class | S1P receptor modulator |
| Target | S1PR1 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
By binding to S1PR1, NPC-16 reduces the migration of immune cells to sites of inflammation, which may help to reduce the severity of autoimmune diseases. This mechanism of action is thought to be beneficial in the treatment of multiple sclerosis and other autoimmune conditions.
Approved indications
- Relapsing forms of multiple sclerosis
Common side effects
- Headache
- Nausea
- Diarrhea
- Fatigue
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |